{
    "organizations": [],
    "uuid": "aca8ce97efd142fe73745c14258b2f40a4e95fc3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-sobi-says-received-approval-from-h/brief-sobi-says-received-approval-from-health-canada-for-once-daily-dosing-of-orfadin-for-treatment-of-ht-1-idUSFWN1RU0XS",
    "ord_in_thread": 0,
    "title": "BRIEF-SOBI Says Received Approval From Health Canada For Once-Daily Dosing Of Orfadin For Treatment Of HT-1",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 13 PM / Updated 24 minutes ago BRIEF-SOBI Says Received Approval From Health Canada For Once-Daily Dosing Of Orfadin For Treatment Of HT-1 Reuters Staff 1 Min Read \nApril 17 (Reuters) - Swedish Orphan Biovitrum AB (publ) : \n* SOBI SAYS RECEIVED APPROVAL FROM HEALTH CANADA FOR ONCE-DAILY DOSING OF ORFADIN FOR TREATMENT OF HT-1 Source text for Eikon: Further company coverage:",
    "published": "2018-04-17T15:13:00.000+03:00",
    "crawled": "2018-04-17T15:30:53.056+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "say",
        "received",
        "approval",
        "health",
        "canada",
        "dosing",
        "orfadin",
        "treatment",
        "reuters",
        "staff",
        "min",
        "read",
        "april",
        "reuters",
        "swedish",
        "orphan",
        "biovitrum",
        "ab",
        "publ",
        "sobi",
        "say",
        "received",
        "approval",
        "health",
        "canada",
        "dosing",
        "orfadin",
        "treatment",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}